JP2004527566A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004527566A5 JP2004527566A5 JP2002586917A JP2002586917A JP2004527566A5 JP 2004527566 A5 JP2004527566 A5 JP 2004527566A5 JP 2002586917 A JP2002586917 A JP 2002586917A JP 2002586917 A JP2002586917 A JP 2002586917A JP 2004527566 A5 JP2004527566 A5 JP 2004527566A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- pharmaceutical composition
- composition according
- octahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 76
- 239000008194 pharmaceutical composition Substances 0.000 claims 44
- -1 cyclohexanecarbonyl group Chemical group 0.000 claims 34
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 claims 29
- 229910052736 halogen Inorganic materials 0.000 claims 24
- 150000002367 halogens Chemical group 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 150000002431 hydrogen Chemical class 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
- 241000710831 Flavivirus Species 0.000 claims 12
- 102000004366 Glucosidases Human genes 0.000 claims 12
- 108010056771 Glucosidases Proteins 0.000 claims 12
- 125000002252 acyl group Chemical group 0.000 claims 12
- 239000003112 inhibitor Substances 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 241000700605 Viruses Species 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 230000029812 viral genome replication Effects 0.000 claims 5
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 241000711549 Hepacivirus C Species 0.000 claims 4
- 241000710842 Japanese encephalitis virus Species 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- 241001474791 Proboscis Species 0.000 claims 4
- 206010037660 Pyrexia Diseases 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 125000001589 carboacyl group Chemical group 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 239000000460 chlorine Substances 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 230000036737 immune function Effects 0.000 claims 3
- ATCRIUVQKHMXSH-UHFFFAOYSA-M 2,4-dichlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1Cl ATCRIUVQKHMXSH-UHFFFAOYSA-M 0.000 claims 2
- XXHDAWYDNSXJQM-UHFFFAOYSA-N 3-hexenoic acid Chemical compound CCC=CCC(O)=O XXHDAWYDNSXJQM-UHFFFAOYSA-N 0.000 claims 2
- TUXYZHVUPGXXQG-UHFFFAOYSA-M 4-bromobenzoate Chemical compound [O-]C(=O)C1=CC=C(Br)C=C1 TUXYZHVUPGXXQG-UHFFFAOYSA-M 0.000 claims 2
- 241001118702 Border disease virus Species 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 2
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 claims 2
- 208000001726 Classical Swine Fever Diseases 0.000 claims 2
- 241000710777 Classical swine fever virus Species 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 2
- 206010054261 Flavivirus infection Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims 2
- 201000005805 Murray valley encephalitis Diseases 0.000 claims 2
- 208000011448 Omsk hemorrhagic fever Diseases 0.000 claims 2
- 241000710778 Pestivirus Species 0.000 claims 2
- 206010041896 St. Louis Encephalitis Diseases 0.000 claims 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims 2
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims 2
- 201000006449 West Nile encephalitis Diseases 0.000 claims 2
- 206010057293 West Nile viral infection Diseases 0.000 claims 2
- 208000003152 Yellow Fever Diseases 0.000 claims 2
- 241000710772 Yellow fever virus Species 0.000 claims 2
- 208000008921 border disease Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229960002248 meradimate Drugs 0.000 claims 2
- 229940095102 methyl benzoate Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- CHXZRHMQQRUVHF-UHFFFAOYSA-N thiophene A Natural products CC#CC1=CC=C(C#CC#CC=C)S1 CHXZRHMQQRUVHF-UHFFFAOYSA-N 0.000 claims 2
- 229940051021 yellow-fever virus Drugs 0.000 claims 2
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 1
- 229930010555 Inosine Natural products 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 101800001530 Thymosin alpha Proteins 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229960003786 inosine Drugs 0.000 claims 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 229960000951 mycophenolic acid Drugs 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0110832.3A GB0110832D0 (en) | 2001-05-03 | 2001-05-03 | Antiviral compounds |
| PCT/EP2002/004944 WO2002089780A2 (en) | 2001-05-03 | 2002-05-02 | Antiviral compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005161641A Division JP4406383B2 (ja) | 2001-05-03 | 2005-06-01 | 抗ウイルス化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004527566A JP2004527566A (ja) | 2004-09-09 |
| JP2004527566A5 true JP2004527566A5 (https=) | 2005-12-22 |
Family
ID=9913938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002586917A Ceased JP2004527566A (ja) | 2001-05-03 | 2002-05-02 | 抗ウイルス化合物 |
| JP2005161641A Expired - Lifetime JP4406383B2 (ja) | 2001-05-03 | 2005-06-01 | 抗ウイルス化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005161641A Expired - Lifetime JP4406383B2 (ja) | 2001-05-03 | 2005-06-01 | 抗ウイルス化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7601735B2 (https=) |
| EP (1) | EP1387681B1 (https=) |
| JP (2) | JP2004527566A (https=) |
| KR (1) | KR100660241B1 (https=) |
| CN (1) | CN100428936C (https=) |
| AT (1) | ATE405261T1 (https=) |
| AU (1) | AU2002341155B2 (https=) |
| CA (1) | CA2445271A1 (https=) |
| CY (1) | CY1110437T1 (https=) |
| DE (1) | DE60228436D1 (https=) |
| DK (1) | DK1387681T3 (https=) |
| ES (1) | ES2312587T3 (https=) |
| GB (1) | GB0110832D0 (https=) |
| IL (2) | IL158558A0 (https=) |
| NO (1) | NO326292B1 (https=) |
| NZ (1) | NZ529448A (https=) |
| PT (1) | PT1387681E (https=) |
| WO (1) | WO2002089780A2 (https=) |
| ZA (1) | ZA200308483B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0116643D0 (en) * | 2001-07-09 | 2001-08-29 | Virogen Ltd | Antiviral compounds |
| GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
| US20060052414A1 (en) * | 2004-08-13 | 2006-03-09 | Migenix, Inc. | Compositions and methods for treating or preventing Hepadnaviridae infection |
| EA200700718A1 (ru) * | 2004-10-06 | 2007-12-28 | Мидженикс Инк. | Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения |
| KR20070102741A (ko) * | 2005-02-09 | 2007-10-19 | 미게닉스 인코포레이티드 | 플라비비리대 감염증을 치료하거나 예방하기 위한 조성물및 방법 |
| JP2007297289A (ja) * | 2006-04-27 | 2007-11-15 | Kitasato Gakuen | 抗ウイルス剤 |
| KR20090057035A (ko) * | 2006-08-21 | 2009-06-03 | 유나이티드 세러퓨틱스 코오포레이션 | 바이러스 감염의 치료를 위한 병용 요법 |
| KR101314166B1 (ko) * | 2011-06-16 | 2013-10-04 | 건국대학교 산학협력단 | 석이버섯 가수분해 효소 추출물 또는 이로로부터 분리된 화합물을 유효성분으로 함유하는 항산화 조성물 |
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| CN102343083A (zh) * | 2011-10-17 | 2012-02-08 | 中国科学院成都生物研究所 | 一种抗病毒的组合药物 |
| SG11201507254VA (en) * | 2013-03-15 | 2015-10-29 | 60 Pharmaceuticals Llc | Novel dosing regimens of celgosivir for the treatment of dengue |
| UA117499C2 (uk) | 2013-09-27 | 2018-08-10 | Мерк Шарп Енд Доум Корп. | Заміщені похідні хінолізину, які можна використовувати як інгібітори інтегрази віл |
| US10046005B2 (en) * | 2014-02-07 | 2018-08-14 | Shaker A. Mousa | Composition and method of use for combinations of anti-viral protease, polymerase inhibitors and natural bioactive compounds in the treatment of hepatitis C infection |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| US11000516B2 (en) * | 2015-12-11 | 2021-05-11 | 60 Degrees Pharmaceuticals, LLC | Dosing regimens of celgosivir for the prevention of dengue |
| BR112018069601A2 (pt) | 2016-03-31 | 2019-01-29 | Janssen Pharmaceuticals Inc | derivados de indolina substituídos como inibidores da replicação viral da dengue |
| BR112018068676A2 (pt) | 2016-03-31 | 2019-01-15 | Janssen Pharmaceuticals Inc | derivados de indol substituídos como inibidores da replicação viral do dengue |
| BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EP3630723B1 (en) | 2017-05-22 | 2022-08-24 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| UA125970C2 (uk) | 2017-05-22 | 2022-07-20 | Янссен Фармасьютікалз, Інк. | Заміщені похідні індоліну як інгібітори реплікації вірусів денге |
| JP7497790B2 (ja) * | 2019-12-27 | 2024-06-11 | 国立大学法人北海道大学 | 豚コレラの治療及び／又は予防剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1315276C (en) | 1987-07-02 | 1993-03-30 | Paul S. Liu | Castanospermine esters and glycosides |
| US5004746A (en) | 1987-09-29 | 1991-04-02 | Merrell Dow Pharmaceuticals Inc. | Anti-retroviral castanospermine esters |
| US4849430A (en) | 1988-03-09 | 1989-07-18 | Monsanto Company | Method of inhibiting virus |
| US5017563A (en) * | 1988-06-23 | 1991-05-21 | Merrell Dow Pharmaceuticals Inc. | Castanospermine esters and glycosides |
| US4970317A (en) | 1989-08-08 | 1990-11-13 | Merrell Dow Pharmaceuticals Inc. | Process for the preparation of castanospermine esters |
| US5066807A (en) | 1990-03-12 | 1991-11-19 | Merrell Dow Pharmaceuticals Inc. | Process for the preparation of castanospermine |
| US5093501A (en) | 1990-03-12 | 1992-03-03 | Merrell Dow Pharmaceuticals Inc. | Intermediates in a process for the preparation of castanospermine |
| GB9027433D0 (en) | 1990-12-18 | 1991-02-06 | Merrell Dow Pharma | Anti-herpes castanospermine esters |
| US5939430A (en) * | 1993-02-22 | 1999-08-17 | Merrell Pharmaceuticals Inc. | Combinations of retroviral inhibitors |
| GB9719189D0 (en) * | 1997-09-09 | 1997-11-12 | Glaxo Group Ltd | New therapeutic method |
| US5959111A (en) | 1997-05-22 | 1999-09-28 | Hoechst Marion Roussel, Inc. | Process for preparing 6-0-monoesters of castanospermine |
| KR20010033028A (ko) * | 1997-12-11 | 2001-04-25 | 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 | 막-관련 바이러스 복제의 억제 |
| WO2001054692A1 (en) | 2000-01-28 | 2001-08-02 | Synergy Pharmaceuticals, Inc. | Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections |
-
2001
- 2001-05-03 GB GBGB0110832.3A patent/GB0110832D0/en not_active Ceased
-
2002
- 2002-05-02 NZ NZ529448A patent/NZ529448A/en not_active IP Right Cessation
- 2002-05-02 US US10/475,830 patent/US7601735B2/en not_active Expired - Lifetime
- 2002-05-02 ES ES02742947T patent/ES2312587T3/es not_active Expired - Lifetime
- 2002-05-02 AT AT02742947T patent/ATE405261T1/de active
- 2002-05-02 IL IL15855802A patent/IL158558A0/xx active IP Right Grant
- 2002-05-02 DE DE60228436T patent/DE60228436D1/de not_active Expired - Lifetime
- 2002-05-02 PT PT02742947T patent/PT1387681E/pt unknown
- 2002-05-02 DK DK02742947T patent/DK1387681T3/da active
- 2002-05-02 CN CNB028099044A patent/CN100428936C/zh not_active Expired - Lifetime
- 2002-05-02 EP EP02742947A patent/EP1387681B1/en not_active Expired - Lifetime
- 2002-05-02 KR KR1020037014319A patent/KR100660241B1/ko not_active Expired - Fee Related
- 2002-05-02 CA CA002445271A patent/CA2445271A1/en not_active Abandoned
- 2002-05-02 WO PCT/EP2002/004944 patent/WO2002089780A2/en not_active Ceased
- 2002-05-02 JP JP2002586917A patent/JP2004527566A/ja not_active Ceased
- 2002-05-02 AU AU2002341155A patent/AU2002341155B2/en not_active Expired
-
2003
- 2003-10-23 IL IL158558A patent/IL158558A/en unknown
- 2003-10-30 ZA ZA200308483A patent/ZA200308483B/en unknown
- 2003-10-31 NO NO20034878A patent/NO326292B1/no not_active IP Right Cessation
-
2005
- 2005-06-01 JP JP2005161641A patent/JP4406383B2/ja not_active Expired - Lifetime
-
2008
- 2008-11-19 CY CY20081101328T patent/CY1110437T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004527566A5 (https=) | ||
| JP2005524632A5 (https=) | ||
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| Luxon et al. | Pegylated interferons for the treatment of chronic hepatitis C infection | |
| AU2002341155B2 (en) | Antiviral compounds | |
| EP2659885A1 (en) | Hepatitis C Antiviral Compositions and Methods | |
| JP2007525518A5 (https=) | ||
| HRP20130098T1 (hr) | MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a | |
| JP2005524628A5 (https=) | ||
| JPH10506640A (ja) | Ｃ型肝炎の処置のためのリバビリンおよびインターフェロンαの使用 | |
| AU2002341155A1 (en) | Antiviral compounds | |
| KR20110054003A (ko) | Ｈｃｖ ｎｓ3 프로테아제 억제제와 인터페론 및 리바비린의 병용물 | |
| WO2005009418A3 (en) | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c | |
| JP2010539241A5 (https=) | ||
| RU2002120922A (ru) | Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием | |
| JP2002515453A5 (https=) | ||
| NO20025600D0 (no) | Fremgangsmåter og sammensetninger for behandling av flavivirus og pestivirus | |
| JP2006522008A (ja) | ウイルス疾患および肝線維症の治療のためのインターフェロン薬物治療 | |
| JP2005535641A5 (https=) | ||
| JP2002326936A5 (https=) | ||
| CN1535724B (zh) | 重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途 | |
| WO2005016288A3 (en) | Methods and compositions for treatment of viral diseases | |
| Clark et al. | Novel interferons for treatment of hepatitis C virus | |
| Ferenci | Treatment of chronic viral hepatitis | |
| JPWO2006033453A1 (ja) | インターフェロン作用物質の活性増強剤 |